While there was a trend toward decreased acute exacerbations in the nintedanib group, this did not reach statistical significance (HR: 0.68, 95% CI: 0.46–1.01). 29 A subsequent subgroup analysis specifically evaluated the effect of nintedanib in autoimmune-ILD.
← all excerpts
Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.
1
—
—